Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 9 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

11%

1 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 1
8(88.9%)
Phase 4
1(11.1%)
9Total
Phase 1(8)
Phase 4(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials
NCT07565441Phase 1Not Yet Recruiting

Drug-Drug Interactions of JMKX003142 in Healthy Participants

Role: collaborator

NCT07470177Phase 1Not Yet Recruiting

A Study to Investigate the Effects of JMKX003142 on QTc Interval in Healthy Adults

Role: collaborator

NCT07463053Phase 1Not Yet Recruiting

Mass Balance and Absolute Bioavailability Study of JMKX003142 In Healthy Volunteers

Role: collaborator

NCT06880848Phase 4Completed

Sonidegib in Adult Patients With Locally Advanced Basal Cell Carcinoma (laBCC) in China

Role: collaborator

NCT06658964Phase 1Not Yet Recruiting

Study to Evaluate the Drug-drug Interaction of JMKX003142 in Healthy Subjects

Role: collaborator

NCT06321250Phase 1Recruiting

A Study of JMKX003948 Tablets in Patients With Renal Cell Carcinoma

Role: collaborator

NCT06344533Phase 1Not Yet Recruiting

Study of JMKX003142 Injection in Chinese Healthy Subjects

Role: collaborator

NCT06079541Phase 1Unknown

Phase 1 Clinical Study of JMKX003142 Tablets

Role: collaborator

NCT05923515Phase 1Unknown

A Phase I Study of JMKX000197 Injection in the Treatment of Malignant Pleural Effusion

Role: collaborator

All 9 trials loaded